175 related articles for article (PubMed ID: 2846576)
1. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.
Davies SM; Robson CN; Davies SL; Hickson ID
J Biol Chem; 1988 Nov; 263(33):17724-9. PubMed ID: 2846576
[TBL] [Abstract][Full Text] [Related]
2. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
3. Isolation and partial characterisation of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays.
Davies SM; Davies SL; Hall AG; Hickson ID
Mutat Res; 1990 Mar; 235(2):111-8. PubMed ID: 2155384
[TBL] [Abstract][Full Text] [Related]
4. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
Smith PJ; Bell SM; Dee A; Sykes H
Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
[TBL] [Abstract][Full Text] [Related]
6. Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
Zwelling LA; Bales E; Altschuler E; Mayes J
Biochem Pharmacol; 1993 Jan; 45(2):516-20. PubMed ID: 8382067
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
[TBL] [Abstract][Full Text] [Related]
8. Isolation of two Chinese hamster ovary cell mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides.
Davies SM; Davies SL; Harris AL; Hickson ID
Cancer Res; 1989 Aug; 49(16):4526-30. PubMed ID: 2545343
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II activity in a DNA double-strand break repair deficient Chinese hamster ovary cell line.
Warters RL; Lyons BW; Li TM; Chen DJ
Mutat Res; 1991 Mar; 254(2):167-74. PubMed ID: 1848351
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.
Glisson B; Gupta R; Hodges P; Ross W
Cancer Res; 1986 Apr; 46(4 Pt 2):1939-42. PubMed ID: 3004712
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.
Glisson BS; Killary AM; Merta P; Ross WE; Siciliano J; Siciliano MJ
Cancer Chemother Pharmacol; 1992; 31(2):131-8. PubMed ID: 1333369
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.
Rogojina AT; Nitiss JL
J Biol Chem; 2008 Oct; 283(43):29239-50. PubMed ID: 18723844
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II as a target of antineoplastic drug therapy.
Zwelling LA
Cancer Metastasis Rev; 1985; 4(4):263-76. PubMed ID: 3000574
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptotic cell death by DNA topoisomerase II inhibitors.
Negri C; Bernardi R; Donzelli M; Scovassi AI
Biochimie; 1995; 77(11):893-9. PubMed ID: 8824770
[TBL] [Abstract][Full Text] [Related]
15. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
16. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
[TBL] [Abstract][Full Text] [Related]
17. Proliferation dependence of topoisomerase II mediated drug action.
Sullivan DM; Glisson BS; Hodges PK; Smallwood-Kentro S; Ross WE
Biochemistry; 1986 Apr; 25(8):2248-56. PubMed ID: 3011082
[TBL] [Abstract][Full Text] [Related]
18. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.
Davies SM; Harris AL; Hickson ID
Nucleic Acids Res; 1989 Feb; 17(4):1337-51. PubMed ID: 2537956
[TBL] [Abstract][Full Text] [Related]
19. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
20. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Baguley BC; Holdaway KM; Fray LM
J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
